What constitutes efficacy for a human immunodefidency virus vaccine that ameliorates viremia: Issues involving surrogate end points in phase 3 trials

Journal of Infectious Diseases

Volumn 188, Issue 2, 2003, Pages 179-193

  Gilbert, Peter B ^a   DeGruttola, Victor G ^c   Hudgens, Michael G ^a   Self, Steven G ^a   Hammer, Scott M ^d   Corey, Lawrence ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE III; DECISION MAKING; DISEASE PROGRESSION; HIV; HIV INFECTIONS; HUMANS; LICENSURE; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 0042315411     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376449     Document Type: Article

References (88)

1. Anderson R, May R. Epidemiological parameters of HIV transmission. Nature 1988; 333:514-9.
2. Anderson RM, Garnett GP. Low-efficacy HIV vaccines: potential for community-based intervention programs. Lancet 1996; 348:1010-3.
3. Esparza J, Bhamarapravti N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 2000; 355:2061-6.
4. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-92.
5. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
6. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106:539-49.
7. Shiver JW, Fu T-M, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 2002; 415:331-5.
8. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3):S197-203.
9. Graham BS. Clinical trials of HIV vaccines. In: Kuiken C, Foley B, Hahn B, et al., eds. HIV Sequence Compendium 2000: theoretical biology and biophysics, group T-10. Los Alamos, NM: Los Alamos National Laboratory, 2000:82-105.
10. Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature 2001; 410:1002-7.
11. Shen X, Siliciano RF. Preventing AIDS but not HIV-1 infection with a DNA vaccine. Science 2000; 290:463-5.
12. International AIDS Vaccine Initiative. State of current AIDS vaccine research. Available at: http://www.iavi.org/
13. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.
14. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
15. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
16. Stover J, Walker N, Garnett GP, et al. Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 2002; 360:73-7.
17. Choopanya K, Tappero J, Pitisuttithum P, et al. Ongoing follow-up of infecting drug users (IDUs) in the AIDSVAX B/E vaccine efficacy trial in Bangkok, Thailand [abstract WeOrD1300]. In: Program and abstracts of the 14th International AIDS Conference (Barcelona). Vol. 2. Stockholm: International AIDS Society, 2002:149.
18. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S325-31.
19. Rida W, Fast P, Hoff R, Fleming T. Intermediate-sized trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:195-203.
20. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-20.
21. Longini IM, Hudgens MG, Halloran ME. Estimation of vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines with partner augmentation. In: Kaplan E, Brookmeyer R, eds. The quantitative evaluation of HIV prevention programs. New Haven, CT: Yale University Press, 2002:241-59.
22. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
23. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-80.
24. Longini IM, Datta S, Halloran ME. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. J Acquir Immun Defic Syndr Hum Retrovirol 1996; 13:440-7.
25. Halloran ME, Struchiner CJ, Longini IM. Study designs for evaluating different efficacy and effectiveness aspects of vaccination. Am J Epidemiol 1997; 146:789-803.
26. Falk LA, Ball LK. Current status and future trends in vaccine regulation: USA. Vaccine 2001; 19:1567-72.
27. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352:1725-30.
28. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
29. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179:717-20.
30. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280:1497-503.
31. Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Nat Vital Stat Rep 1999; 47:1-104.
32. Centers for Disease Control and Prevention. Update: AIDS - United States, 2000. MMWR Morb Mortal Wkly Rep 2002; 51:592-5.
33. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
34. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-13.
35. Fleming TR. Evaluating therapeutic interventions (with Discussion and Rejoinder). Stat Science 1992; 7:428-56.
36. + lymphocytes in patients with AIDS and AIDS-related complex. J Acquire Immun Defic Syndr 1993; 6:359-65.
37. Fleming TR. Surrogate markers in AIDS and cancer trials. Stat Med 1994; 13:1423-35.
38. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res Hum Retroviruses 2000; 16:1123-33.
39. DeGruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Cont Clin Trials 2001;22:485-502.
40. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:1069-76.
41. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105-10.
42. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HW-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70.
43. Albert JM, Ioannidis JPA, Reichelderfer P, et al. Statistical issues for HIV surrogate endpoints: point/counterpoint Stat Med 1998; 17:2435-62.
44. Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000. Approaches to the development of broadly protective HIV vaccines: challenges posed by genetic, biological and antigenic variability of HIV-1. AIDS 2001; 15:W1-25.
45. Lukashov VV, Goudsmit J, Paxton WA. The genetic diversity of HIV-1 and its implications for vaccine development. In: Wong-Staal F, Gallo RC, eds. AIDS vaccine research. New York: Marcel Dekker, 2002:93-120.
46. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205-11.
47. Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94:1890-5.
48. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-7.
49. Goulder PJ, Brander C, Tang Y, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 2001; 412:334-8.
50. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-9.
51. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13:797-804.
52. Staszewski S, DeMasi R, Hill AM, Dawson D. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 1998; 12:1991-7.
53. Katzenstein DA, Hammer SM, Hughes MD, et al. The relationship of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335:1091-8.
54. Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002; 324:1-10.
55. Egger M, May M, Genevieve C, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-28.
56. Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA 2001; 285:777-84.
57. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
58. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334:1011-7.
59. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 4 February 2002. Available at: http://www.aidsinfo.nih.gov/guidelines/
60. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-9.
61. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000; 283:2417-26.
62. World Health Organization. Scaling up antiretroviral therapy in resource limited settings: guidelines for a public health approach, executive summary. April 2002. Available at: http://www.who.int/HIV_AIDS/first.html.
63. Geise R, Maenza J, Celum CL. Clinical challenges and diagnostic approaches to recognizing acute human immunodeficiency virus infection. Am J Med 2001; 111:237-8.
64. Guenter D, Esparza J, Macklin R. Ethical considerations in international HIV vaccine trials: summary of a consultative process conducted by the Joint United Nations Programme on HIV/AIDS (UNAIDS). J Med Ethics 2000; 26:37-43.
65. Rotnitzky A, Robins JM, Scharfstein DO. Semiparametric regression for repeated outcomes with nonignorable nonresponse. J Amer Stat Assoc 1998; 93:1321-39.
66. Liang KY, Zeger SL. Longitudinal data analysis using the generalized linear model. Biometrika 1986; 73:13-22.
67. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer, 2000.
68. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12:1823-32.
69. Pitt J, Brambilla D, Reichelderfer P, et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175:567-75.
70. Gilbert P, Self S, Rao M, Naficy A, Clemens J. Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy depends on genotypic and phenotypic pathogen variation. J Clin Epidemiol 2001; 54:68-85.
71. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-5.
72. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. II. Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001; 134:978-96.
73. Tang J, Shelton B, Makhatadze NJ, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76:662-72.
74. Hudgens MG, Hoering A, Self SG. On the analysis of viral load endpoints in HIV vaccine trials. Stat Med (in press).
75. Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics (in press).
76. Barth-Jones DC, Longini IM. Determining optimal vaccination policy for HIV vaccines: a dynamic simulation model for the evaluation of vaccine policy. In: Andersen JG, Katzper M, eds. Proceedings of the International Conference on Health Sciences Simulation 2002. San Antonio: 2002 Western Multiconference, 2002:63-80.
77. UNAIDS. Report on the global HIV/AIDS epidemic 2002. Available at: http://www.unaids.org/barcelona/presskit/report.htm.
78. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Epidemiol Rev 1988; 10:212-41.
79. Isbell MT, Widdus R. Actions to avoid potential regulatory delays for vaccines against HIV/AIDS. Available at: http://www.iavi.org.
80. Future access to HIV vaccines: report from a WHO-UNAIDS consultation, Geneva, 2-3 October 2000. AIDS 2001; 15:W27-44.
81. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread usage of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-93.
82. + responses. J Clin Invest 2001; 107:341-9.
83. Anderson RM, Swinton J, Garnett GP. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc R Soc Lond B 1995; 261:147-51.
84. O'Connor D, Allen T, Watkins DI. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development? Immunol Lett 2001; 79:77-84.
85. 251 infection of macaques. Nat Med 2000; 6:1140-6.
86. Altfeld M, Rosenberg E, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-180.
87. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11:167-78.
88. Lin DY, Fleming TR, DeGruttola V. Estimating the proportion of treat-ment effect explained by a surrogate marker. Stat Med 1997; 16:1515-27.